Fumihiro Tanaka
-
- Lung Cancer Diagnosis and Treatment 5
- Gastric Cancer Management and Outcomes 4
- Pleural and Pulmonary Diseases 3
- Lung Cancer Treatments and Mutations 3
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 2
-
- Cancer Immunotherapy and Biomarkers 4
- Colorectal Cancer Surgical Treatments 2
-
- Colorectal and Anal Carcinomas 2
Fumihiro Tanaka
10 papers receiving 145 citations
Hit Papers
Peers
Comparison fields: 5 of 13
- Pulmonary and Respiratory Medicine 132
- Oncology 98
- Cancer Research 24
- Psychiatry and Mental health 11
- Radiology, Nuclear Medicine and Imaging 16
Countries citing papers authored by Fumihiro Tanaka
This map shows the geographic impact of Fumihiro Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumihiro Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumihiro Tanaka more than expected).
Fields of papers citing papers by Fumihiro Tanaka
This network shows the impact of papers produced by Fumihiro Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumihiro Tanaka. The network helps show where Fumihiro Tanaka may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fumihiro Tanaka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 2 | |
| 5 | 2025 | 4 | |
| 6 | 2024 | 25 | |
| 7 | 2024 | 9 | |
| 8 | LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLCbreakdown → | 2023 | 67 |
| 9 | 2023 | 13 | |
| 10 | 2022 | 6 | |
| 11 | 2013 | 7 | |
| 12 | 2013 | 11 |
About Fumihiro Tanaka
Fumihiro Tanaka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery, having authored 12 papers that have together received 146 indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (5 papers), Gastric Cancer Management and Outcomes (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Pleural and Pulmonary Diseases (3 papers), Lung Cancer Treatments and Mutations (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers), Colorectal and Anal Carcinomas (2 papers) and Colorectal Cancer Surgical Treatments (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (132 citations), Oncology (98 citations) and Cancer Research (24 citations). Fumihiro Tanaka has collaborated with scholars based in Japan, United States and Spain. Frequent co-authors include Mark M. Awad, Janis M. Taube, Shun Lü, Robin Cornelissen, Libor Havel, Hiroyuki Ito, Luboš Petruželka, Jie He, Padma Sathyanarayana and C. Coronado Erdmann. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Japanese Journal of Clinical Oncology, Interactive Cardiovascular and Thoracic Surgery and International Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.